Log In
Print this Print this

Biosimilar abatacept (M834)

  Manage Alerts
Collapse Summary General Information
Company Momenta Pharmaceuticals Inc.
DescriptionBiosimilar of Orencia abatacept, a CTLA-4 (CD152)-Ig fusion protein
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Inflammation (unspecified)
Indication DetailsTreat inflammatory disorders
Regulatory Designation
PartnerMylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today